Pharmafile Logo

heart attack patients

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

AZ adds to pipeline again with Amplimmune buy

Pharma company pays $500m via its MedImmune subsidiary for the small US biotech

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

National Institute for Health and Care Excellence NICE logo

NICE forced to look again at Alimta

Procedural error forces watchdog to reconsider rejection of Lilly's lung cancer

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

AZ inks $815m deal for FibroGen anaemia drug

Deal comes as company reveals second quarter performance

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

NICE demands more data from Roche for MabThera in rare autoimmune disease

Unable to recommend expanding drug’s indication to include vasculitis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links